Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan

Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan

BackgroundThe NAPOLI-1 trial demonstrated that liposomal irinotecan in combination with fluorouracil (5-FU) and leucovorin (LV) prolonged survival with a manageable safety profile in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy....

Full description

Bibliographic Details
Main Authors: Kenneth H. Yu, Andrew E. Hendifar, Olatunji B. Alese, Amber Draper, Maen Abdelrahim, Ethan Burns, Gazala Khan, Paul Cockrum, Rachel H. Bhak, Catherine Nguyen, Maral DerSarkissian, Mei Sheng Duh, Nathan Bahary
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Oncology
Subjects:
metastasis
pancreatic ductal adenocarcinoma
cancer management
pancreatic cancer
liposomal irinotecan
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.678070/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.678070/full

Similar Items